
This study analyzed 226 patients who received Impella 5.5 support for cardiogenic shock, finding higher mortality in SCAI stage E (35%) and higher survival without advanced therapies in stages A-B (95%, 90%). It concluded that stratifying patients by shock stages helps guide decisions on Impella 5.5 support.
Like
Save
Share